WO2008005565A3 - Antiviral phosphinate compounds - Google Patents

Antiviral phosphinate compounds Download PDF

Info

Publication number
WO2008005565A3
WO2008005565A3 PCT/US2007/015664 US2007015664W WO2008005565A3 WO 2008005565 A3 WO2008005565 A3 WO 2008005565A3 US 2007015664 W US2007015664 W US 2007015664W WO 2008005565 A3 WO2008005565 A3 WO 2008005565A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
phosphinate compounds
antiviral
antiviral phosphinate
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/015664
Other languages
French (fr)
Other versions
WO2008005565A9 (en
WO2008005565A2 (en
Inventor
Anthony Casarez
Kleem Chaudhary
Aesop Cho
Michael Clarke
Edward Doerffler
Maria Fardis
Choung U Kim
Hyungjung Pyun
Xiaoning C Sheng
Jianying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2007269567A priority Critical patent/AU2007269567B2/en
Priority to JP2009518397A priority patent/JP2009542698A/en
Priority to AP2008004721A priority patent/AP2008004721A0/en
Priority to ES07796752T priority patent/ES2388969T3/en
Priority to AT07796752T priority patent/ATE554776T1/en
Priority to US12/303,219 priority patent/US20090227491A1/en
Priority to EP07796752A priority patent/EP2043658B1/en
Priority to HR20090076A priority patent/HRP20090076A2/en
Priority to CA2656356A priority patent/CA2656356C/en
Priority to EA200900154A priority patent/EA018098B1/en
Priority to MX2009000236A priority patent/MX2009000236A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority to BRPI0713961-6A priority patent/BRPI0713961A2/en
Priority to HK09106472.5A priority patent/HK1127295B/en
Publication of WO2008005565A2 publication Critical patent/WO2008005565A2/en
Publication of WO2008005565A3 publication Critical patent/WO2008005565A3/en
Priority to IL195489A priority patent/IL195489A0/en
Priority to ZA2008/10400A priority patent/ZA200810400B/en
Anticipated expiration legal-status Critical
Publication of WO2008005565A9 publication Critical patent/WO2008005565A9/en
Priority to NO20090596A priority patent/NO20090596L/en
Priority to ZA2011/07393A priority patent/ZA201107393B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
PCT/US2007/015664 2006-07-07 2007-07-06 Antiviral phosphinate compounds Ceased WO2008005565A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MX2009000236A MX2009000236A (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds.
AP2008004721A AP2008004721A0 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
ES07796752T ES2388969T3 (en) 2006-07-07 2007-07-06 Phosphinate Antiviral Compounds
AT07796752T ATE554776T1 (en) 2006-07-07 2007-07-06 ANTIVIRAL PHOSPHINATE COMPOUNDS
US12/303,219 US20090227491A1 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
EP07796752A EP2043658B1 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
BRPI0713961-6A BRPI0713961A2 (en) 2006-07-07 2007-07-06 antiviral phosphinate compounds
JP2009518397A JP2009542698A (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
EA200900154A EA018098B1 (en) 2006-07-07 2007-07-06 Phosphinate compounds (embodiments)
AU2007269567A AU2007269567B2 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
CA2656356A CA2656356C (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
HR20090076A HRP20090076A2 (en) 2006-07-07 2007-07-06 ANTI-VIRUS PHOSPHINATE COMPOUNDS
HK09106472.5A HK1127295B (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds
IL195489A IL195489A0 (en) 2006-07-07 2008-11-25 Antiviral phosphinate compounds
ZA2008/10400A ZA200810400B (en) 2006-07-07 2008-12-09 Antiviral phosphinate compounds
NO20090596A NO20090596L (en) 2006-07-07 2009-02-06 Antiviral phosphinate compounds
ZA2011/07393A ZA201107393B (en) 2006-07-07 2011-10-10 Antiviral phosphinate compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81948806P 2006-07-07 2006-07-07
US60/819,488 2006-07-07
US83290806P 2006-07-24 2006-07-24
US60/832,908 2006-07-24

Publications (3)

Publication Number Publication Date
WO2008005565A2 WO2008005565A2 (en) 2008-01-10
WO2008005565A3 true WO2008005565A3 (en) 2008-05-02
WO2008005565A9 WO2008005565A9 (en) 2009-01-29

Family

ID=38626760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015664 Ceased WO2008005565A2 (en) 2006-07-07 2007-07-06 Antiviral phosphinate compounds

Country Status (19)

Country Link
US (4) US7893264B2 (en)
EP (2) EP2043658B1 (en)
JP (3) JP2009542698A (en)
KR (1) KR20090026216A (en)
CN (1) CN102532198A (en)
AR (1) AR061840A1 (en)
AT (1) ATE554776T1 (en)
AU (1) AU2007269567B2 (en)
BR (1) BRPI0713961A2 (en)
CA (1) CA2656356C (en)
EA (1) EA018098B1 (en)
ES (2) ES2388969T3 (en)
HR (1) HRP20090076A2 (en)
IL (1) IL195489A0 (en)
MX (1) MX2009000236A (en)
NO (1) NO20090596L (en)
TW (1) TW200819460A (en)
WO (1) WO2008005565A2 (en)
ZA (1) ZA200810400B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152171A (en) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) NEW HEPATITIS C VIRAL REPLICATION INHIBITORS
TW200819460A (en) 2006-07-07 2008-05-01 Gilead Sciences Inc Antiviral phosphinate compounds
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2403860B1 (en) * 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
AR077125A1 (en) * 2009-06-23 2011-08-03 Gilead Sciences Inc PHARMACEUTICAL COMBINATIONS USEFUL TO TREAT HCV
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
AU2011349844B2 (en) * 2010-12-20 2017-06-01 Gilead Sciences, Inc. Combinations for treating HCV
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SE1450131A1 (en) 2011-10-21 2014-05-07 Abbvie Inc DAA combination therapy (eg with ABT-072 or ABT-333) for use in the treatment of HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012002748T5 (en) 2011-10-21 2014-07-31 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
EA025560B1 (en) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
PT2950786T (en) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN103539833B (en) * 2013-09-29 2016-02-03 北京林业大学 High reactivity alpha-glucosaccharase enzyme inhibition peptide and its production and use
CN103539831B (en) * 2013-09-29 2016-02-03 北京林业大学 Ansu apricot alpha-glucosaccharase enzyme inhibition peptide and its production and use
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
CN109414508A (en) 2016-05-27 2019-03-01 吉利德科学公司 Methods of treating hepatitis B virus infection using NS5A, NS5B or NS3 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004977A (en) * 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
WO2006020276A2 (en) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Antiviral compounds
WO2006109085A1 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
ATE131825T1 (en) 1990-06-13 1996-01-15 Arnold Glazier PHOSPHORYLATED PRODRUGS
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
DE4308096A1 (en) 1993-03-13 1994-09-15 Hoechst Ag Prodrug derivatives of enzyme inhibitors with hydroxyl groups, process for their preparation and their use
ATE199906T1 (en) 1993-06-29 2001-04-15 Mitsubishi Chem Corp PHOSPHONATE NUCLEOTIDE ESTER DERIVATIVES
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
JPH07183249A (en) * 1993-12-22 1995-07-21 Nec Yamagata Ltd Ion implantation process control method
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5968788A (en) * 1995-08-28 1999-10-19 Toray Industries, Inc. Method for producing folic acid
DE19843360A1 (en) * 1998-09-22 2000-03-30 Hassan Jomaa New phosphororganic compounds; useful for treatment of bacterial, viral and parasitic infection, and as herbicides or for treating infections in plants
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
ES2320771T3 (en) 2003-04-16 2009-05-28 Bristol-Myers Squibb Company PEPTIDIC INHIBITORS OF MACROCICLIC ISOQUINOLINE VIRUS OF HEPATITIS C.
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2006276246B2 (en) * 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
PE20070211A1 (en) 2005-07-29 2007-05-12 Medivir Ab MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200819460A (en) 2006-07-07 2008-05-01 Gilead Sciences Inc Antiviral phosphinate compounds
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
AR077125A1 (en) 2009-06-23 2011-08-03 Gilead Sciences Inc PHARMACEUTICAL COMBINATIONS USEFUL TO TREAT HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004977A (en) * 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
WO2006020276A2 (en) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Antiviral compounds
WO2006109085A1 (en) * 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
WO2007014922A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRAY ET AL: "Synthesis of substituted 5-aminomethyl tetrahydro-isoquinolines and dihydro-isoindoles", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 62, no. 29, 21 May 2006 (2006-05-21), pages 6869 - 6875, XP005496592, ISSN: 0040-4020 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV

Also Published As

Publication number Publication date
CN102532198A (en) 2012-07-04
ATE554776T1 (en) 2012-05-15
US8586744B2 (en) 2013-11-19
US20080057031A1 (en) 2008-03-06
US8674088B2 (en) 2014-03-18
EP2422791A1 (en) 2012-02-29
ES2388969T3 (en) 2012-10-22
EP2422791B1 (en) 2014-12-17
IL195489A0 (en) 2009-09-01
US20110082112A1 (en) 2011-04-07
NO20090596L (en) 2009-04-01
HRP20090076A2 (en) 2009-05-31
AU2007269567A1 (en) 2008-01-10
US20090227491A1 (en) 2009-09-10
MX2009000236A (en) 2009-01-23
CA2656356A1 (en) 2008-01-10
EA018098B1 (en) 2013-05-30
JP2012107061A (en) 2012-06-07
CA2656356C (en) 2013-04-09
KR20090026216A (en) 2009-03-11
BRPI0713961A2 (en) 2012-11-27
ES2531315T3 (en) 2015-03-12
US20110081314A1 (en) 2011-04-07
EP2043658A2 (en) 2009-04-08
HK1127295A1 (en) 2009-09-25
ZA200810400B (en) 2011-12-28
AR061840A1 (en) 2008-09-24
EP2043658B1 (en) 2012-04-25
JP2009542698A (en) 2009-12-03
EA200900154A1 (en) 2009-06-30
JP2015083605A (en) 2015-04-30
AU2007269567B2 (en) 2012-11-08
US7893264B2 (en) 2011-02-22
WO2008005565A9 (en) 2009-01-29
JP6010640B2 (en) 2016-10-19
WO2008005565A2 (en) 2008-01-10
TW200819460A (en) 2008-05-01

Similar Documents

Publication Publication Date Title
WO2008005565A3 (en) Antiviral phosphinate compounds
WO2009005677A3 (en) Antiviral compounds
WO2009005676A3 (en) Antiviral compounds
WO2009005690A3 (en) Antiviral compounds
WO2006020276A3 (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2012068234A3 (en) Antiviral compounds
WO2007009109A3 (en) Antiviral compounds
WO2009111653A3 (en) Antiviral therapeutic agents
TW200738742A (en) Antiviral compounds
SG176015A1 (en) Antiviral compounds
WO2008089105A3 (en) Antiviral nucleoside analogs
WO2010121576A3 (en) Novel 7-deazapurine nucleosides for therapeutic uses
WO2005002626A3 (en) Therapeutic phosphonate compounds
WO2004096285A3 (en) Anti-infective phosphonate conjugates
WO2008048589A3 (en) Compounds and methods for treatment of hcv
WO2007014352A3 (en) Antiviral phosphonate conjugates for inhibition of hiv
UA103329C2 (en) Normal;heading 1;heading 2;heading 3;SALTS OF HIV INHIBITOR COMPOUNDS
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2008033935A3 (en) Vinorelbine derivatives
WO2008098143A3 (en) Antimicrobial compounds and methods of use
UA92464C2 (en) Antiviral compounds
UA96295C2 (en) Antiviral phosphinate compounds
UA98333C2 (en) Antiviral compounds
WO2008038094A3 (en) Process for the preparation of pure adenosine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780025596.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796752

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 573061

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007269567

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2656356

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009518397

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000236

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2007269567

Country of ref document: AU

Date of ref document: 20070706

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 180/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007796752

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20090076A

Country of ref document: HR

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: a200814197

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 1020097002642

Country of ref document: KR

Ref document number: 200900154

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12303219

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0713961

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090107